Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib - Clinical Lung Cancer
Table 1 from Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib | Semantic Scholar
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - ScienceDirect
Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib — ALK POSITIVE
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation - Lung Cancer
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study | Journal of Translational Medicine | Full Text
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin. - ppt download
MEK inhibitors against MET-amplified non-small cell lung cancer
![PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/d4b56019bf1c5c867f8dd86ecce095a3a9e8eeb2/3-Figure2-1.png "PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar")
PDF] Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. | Semantic Scholar
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study | Trials | Full Text
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer | British Journal of Cancer
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
Downregulation of MET in H1993 cells, effects of crizotinib on EGFR... | Download Scientific Diagram
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Effect of Crizotinib on c-MET expression in c-MET altered cancer cells.... | Download Scientific Diagram
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing - Lung Cancer
